For the Inventor, By the Inventor

Enter assignee name

Nanjing Legend Biotech Co., Ltd.

USPTO Granted Patents = 15

EPO Patents = 1

Trademarks = 4

Forward Citations = 5

Loading Chart...

Loading Chart...

36 inventors (with patents filed for the assignee):

Shu Wu (10 out of 15 patents)

Chuan-Chu Chou (9 out of 20 patents)

Shuai Yang (9 out of 13 patents)

4. Yafeng Zhang (5 out of 10 patents)

5. Qiuchuan Zhuang (4 out of 8 patents)

6. Xiaohu Fan (3 out of 7 patents)

7. Pingyan Wang (3 out of 7 patents)

8. Lei Yang (3 out of 7 patents)

9. Liusong Yin (2 out of 6 patents)

10. Wang Zhang (2 out of 6 patents)

11. Jiaying Hao (1 out of 5 patents)

12. Jianbing Zhang (1 out of 3 patents)

13. Bo Wu (1 out of 8 patents)

14. Fang Liang Zhang (1 out of 13 patents)

15. Jian Liu (1 out of 5 patents)

15 patents: Sort by Forward Citations

1. 12258418 - Claudin18.2 binding moieties and uses thereof (2025-03-25),

2. 12168688 - Antibodies and variants thereof against PD-L1 (2024-12-17),

3. 11958903 - Single-domain antibodies against LAG-3 and uses thereof (2024-04-16),

4. 11932698 - Anti-mesothelin chimeric antigen receptor (CAR) constructs and uses thereof (2024-03-19),

5. 11905327 - Single-domain antibodies and variants thereof against TIGIT (2024-02-20),

6. 11827713 - Chimeric antibody immune effector cell engagers and methods of use thereof (2023-11-28),

7. 11713353 - Single-domain antibodies and variants thereof against PD-1 (2023-08-01),

8. 11708410 - Antibodies and variants thereof against TIGIT (2023-07-25),

9. 11673954 - Single-domain antibodies and variants thereof against PD-L1 (2023-06-13),

10. 11564945 - Chimeric antigen receptor and use thereof (2023-01-31),

11. 11505601 - Compositions and methods using a single-domain antibody binding transferrin and protein A for increasing protein half-life in serum (2022-11-22),

12. 11472881 - Single-domain antibodies and variants thereof against CTLA-4 (2022-10-18),

13. 11447573 - Multispecific antigen binding proteins and methods of use thereof (2022-09-20),

14. 11401317 - Human-CD123-targeting chimeric receptor ligand and application thereof (2022-08-02),

15. 11168146 - Compositions and methods for increasing protein half-life in a serum (2021-11-09),

Nanjing Legend Biotech Co., Ltd. is a leading biotechnology company specializing in the development and commercialization of innovative cell therapies for the treatment of cancer and other serious diseases. The company is at the forefront of advancing cutting-edge technologies to deliver transformative treatments to patients in need.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

15 Patents

#24 in Nanjing

#1,708 in China

#38,719 in the World

Nanjing Legend Biotech Co., Ltd.

Forward Citations = 5

36 inventors:

Shu Wu (10 out of 15 patents)

Chuan-Chu Chou (9 out of 20 patents)

Shuai Yang (9 out of 13 patents)

4. Yafeng Zhang (5 out of 10 patents)

5. Qiuchuan Zhuang (4 out of 8 patents)

Please report any incorrect information to support@idiyas.com

Loading…